Bluebird Bio Inc. (NASDAQ:BLUE)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $47.46, but opened at $48.09. Bluebird Bio shares last traded at $49.30, with a volume of 668,449 shares changing hands.

Several equities analysts have recently commented on the stock. Wells Fargo & Co. restated a “buy” rating on shares of Bluebird Bio in a research report on Thursday, May 5th. Goldman Sachs Group Inc. reiterated a “buy” rating and set a $149.00 price objective on shares of Bluebird Bio in a research report on Monday, April 11th. Vetr upgraded shares of Bluebird Bio from a “buy” rating to a “strong-buy” rating and set a $61.43 price objective for the company in a research report on Thursday, April 7th. Wedbush reiterated an “outperform” rating and set a $117.00 price objective on shares of Bluebird Bio in a research report on Thursday, May 5th. Finally, Maxim Group reiterated a “buy” rating and set a $105.00 price objective on shares of Bluebird Bio in a research report on Wednesday, April 20th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the stock. Bluebird Bio presently has an average rating of “Buy” and a consensus price target of $96.09.

The company’s 50 day moving average price is $44.33 and its 200-day moving average price is $45.59. The stock’s market cap is $1.82 billion.

Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, May 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.29. The business had revenue of $1.50 million for the quarter, compared to analyst estimates of $4.50 million. During the same period in the previous year, the firm posted ($0.76) EPS. Bluebird Bio’s revenue was down 76.2% compared to the same quarter last year. On average, equities research analysts anticipate that Bluebird Bio Inc. will post ($5.90) earnings per share for the current year.

In other Bluebird Bio news, insider Philip D. Gregory sold 2,931 shares of Bluebird Bio stock in a transaction that occurred on Thursday, June 16th. The shares were sold at an average price of $39.52, for a total transaction of $115,833.12. Following the completion of the sale, the insider now directly owns 30,069 shares in the company, valued at $1,188,326.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Davidson sold 1,000 shares of Bluebird Bio stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $38.73, for a total transaction of $38,730.00. Following the sale, the insider now owns 10,600 shares of the company’s stock, valued at $410,538. The disclosure for this sale can be found here.

Other large investors recently made changes to their positions in the company. ProShare Advisors LLC raised its stake in shares of Bluebird Bio by 6.5% in the fourth quarter. ProShare Advisors LLC now owns 30,869 shares of the company’s stock valued at $1,982,000 after buying an additional 1,888 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Bluebird Bio by 6.0% in the fourth quarter. Rhumbline Advisers now owns 35,855 shares of the company’s stock valued at $2,303,000 after buying an additional 2,023 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of Bluebird Bio by 6.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 37,859 shares of the company’s stock valued at $2,431,000 after buying an additional 2,385 shares during the last quarter. Nationwide Fund Advisors raised its stake in shares of Bluebird Bio by 40.8% in the fourth quarter. Nationwide Fund Advisors now owns 40,800 shares of the company’s stock valued at $2,620,000 after buying an additional 11,830 shares during the last quarter. Finally, GAM Holding AG bought a new stake in shares of Bluebird Bio during the fourth quarter valued at about $2,717,000.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.